GlassScriptPhysician profile
Wallace Coleman Baker
NPI 1083696967
$12,603.19
in general payments reported to CMS, 2019-2025
66 companies · $1,803 in 2025
The $1,803 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $1,426 · 2021: $1,980 · 2022: $1,895 · 2023: $1,658 · 2024: $2,402 · 2025: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,863.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,660.12 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $992.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $889.16 | 2019-2025 | Evenity, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $649.67 | 2020-2025 | Rexulti |
| Novo Nordisk INC | $632.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $542.95 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Grifols USA, LLC | $478.96 | 2021-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $404.91 | 2019-2025 | Xarelto, Spravato |
| Pfizer INC. | $371.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $294.69 | 2019-2024 | Breztri, Farxiga, Flumist Quadrivalent |
| Novartis Pharmaceuticals Corporation | $280.91 | 2021-2024 | |
| Astellas Pharma US INC | $278.99 | 2019-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $273.59 | 2022-2024 | Qelbree, Qelbree |
| Allergan, INC. | $250.14 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $249.34 | 2019-2022 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.